The Safety and Effectiveness of Protease Inhibitors and Non-Nucleoside Reverse Transcriptase Inhibitors for Pregnant Women

Abstract

This article investigated the efficacy and safety of antiretroviral medication (ART), namely protease inhibitors (PI) and non-nucleoside reverse transcriptase inhibitors (NNRTI), used by HIV/AIDS pregnant women. It emphasizes the relevance of ART management throughout pregnancy for maternal and child health, aiming to teach doctors and improve outcomes at the maternal and child levels. Objective. To study how HIV-infected pregnant women’s PI and NNRTI efficacy and clarity affect mother’s and baby’s health. Method. A systematic review was undertaken between 2002 and 2021 to assess the similarity groups of HIV-positive pregnant women and their fetuses. The analysis compared the effects of PI-containing and NNRTI-based ART. Over 45,000 pregnant women from 27 nations were analyzed in studies, with each receiving a distinct technique rating. Results. The systematic review included 10 studies in total, with 45,427 women participating. The findings revealed that there was no significant connection between PIs and NNRTIs for various fetal/neonatal outcomes. Therapeutic drug monitoring should be performed on PIs and NNRTI regimens with a small therapeutic window, respectively. The study of antiretroviral medicines with pregnant women indicated that both drug classes were safe throughout pregnancy, with PI-based regimens showing greater efficiency in achieving viral suppression. Hearing early ART initiation resulted in better neonatal outcomes. Conclusion. ART therapy for HIV-positive pregnant women must prevent toxicity and inadequate medication distribution. PIs reduce perinatal risk and inhibit viruses. Understanding patient-drug interactions is crucial because starting ARTs late is dangerous. Go-ahead tracking enhances mother and infant health, HIV-related pregnancy outcomes, and HIV management.